US Pharma MarketingAdam Friedman, CEO of the Scorpion Therapeutics spinout, said the deal helps both companies accelerate research "faster than either of us could alone."
Antares gets $105M from Novartis for new cancer drugs
Adam Friedman, CEO of the Scorpion Therapeutics spinout, said the deal helps both companies accelerate research "faster than either of us could alone."
Source: BioPharma Dive